看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
- Y& o7 D) b& g0 ^) z4 G1 a+ m6 _- }. p6 O2 u
8 e5 q) \ q2 Y. |# z) e2 A
Currently available feasibility data for possible combination strategies.
& [7 L9 }% Y% I/ E# y4 t————————————————————————————————
/ c/ G5 ~1 ^' R# y% q" j( `% VCombination Feasibility according to preliminary data
( T: U& E- r6 T/ ^8 a, `" b" f——————————————————————————————————5 C" Q6 h) g. H# F% I- [2 o# b1 v
Bevacizumab + sorafenib Yes, reduced dose
( r% U9 s3 h9 @( y- f1 KBevacizumab + sunitinib† No % d6 S9 J/ O0 ~) F: e. G, u) |; ]
Bevacizumab + temsirolimus Yes ! T7 L6 j c$ c- d
Bevacizumab + everolimus Yes * \5 i/ y4 d5 |
Sorafenib + sunitinib ? : u3 Q* V3 W8 `' I
Sorafenib + temsirolimus Yes, reduced dose
4 a6 b/ G& T$ f* f' K" DSorafenib + everolimus Yes, reduced dose 6 s" ]7 A3 |$ ~4 G1 [
Sunitinib + temsirolimus† No
$ O- c$ D \4 jSunitinib + everolimus ? ( X; J* P4 c& F' X0 \, k9 k
Temsirolimus + everolimus ?
- Y2 o0 O) j' Y, \————————————————————
6 P) z- h8 N* H; C" B- `†Led to US FDA warning.
H0 r R- p! W, C?: As yet unattempted combination.
* F! ~# A6 f; c& x2 G |
显身卡
